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Prurigo nodularis (PN) is a chronic skin disease, charac-
terized by severe pruritus and multiple hyperkeratotic 
nodules often located on the extensor part of the upper 
and lower extremities (1). 
The pathogenesis of PN is unknown; however, various 
hypotheses have been proposed including: increased level 
of substance P (a neuropeptide and a well-known mediator 
of pruritus) in the small nerve fibres in the dermis (2, 3); 
upregulation of nerve growth factor (NGF) in the dermis, 
leading to modulation of the small nerve fibres (4); and 
increased levels of interleukin-31 (IL-31) in the blood (5). 
PN is defined as a subtype of chronic prurigo and is 
considered to be a distinct condition, which may originate 
in underlying comorbidities, such as atopic dermatitis 
(AD), neurological or systemic diseases (6). 
PN is often burdensome to patients, due to severe 
pruritus leading to reduced quality of life (QoL), lack 
of sleep, and negative impact on everyday life (7). The 
existing treatments include topical corticosteroids, zinc 
dressing treatment, ultraviolet B (UVB), immunosuppres-
sants, gabapentin, antidepressants, and thalidomide, all 
with limited effect. Overall, there is a need for effective 
treatments, as a large part of the existing therapies are 
unable to reduce disease severity and are associated with 
a poor safety profile (8). 
In clinical trials, treatment with the phosphodiesterase-4 
(PDE4) inhibitor (apremilast) has resulted in significant 
reduction in pruritus in AD and psoriasis (9, 10). The aim 
of this pilot-study was to evaluate the efficacy of apremi-
last in patients with PN.
MATERIALS AND METHODS (see Appendix SI1)
RESULTS
A total of 10 patients (5 women) with PN were enrolled 
in the study. Mean ± SD age was 61.7 ± 10.0 years. All 
patients had lesions on at least arms and legs and 6 had 
previously received systemic therapy. Table SI1 shows the 
patient characteristics. 
Seven patients completed the study, one of whom took 
a 4-week sunny vacation during week 5, thus data from 
week 4 for this patient was carried forward, although the 
patient completed the study. Three patients withdrew 
consent or were excluded before week 16; one at week 
11 due to intermittent fever, and 2 at week 10, both due 
to lack of effect. 
Patients experienced only minor or no reduction in 
pruritus; 3 patients had an improvement in visual ana-
logue scale (VAS) pruritus ≥ 3 points, with a mean VAS 
at baseline of 8.7 ± 0.9 to 7.4 ± 2.4 at week 12. Overall, 
there was no clinical improvement following treatment 
with apremilast from baseline to the end of the trial, thus 
none of the 10 patients had an improvement in Physician 
Global Assessment (PGA) ≥ 2 points, with a mean PGA at 
baseline of 3.5 ± 0.5 to 3.2 ± 0.8 at week 12 (Table SI1 and 
Fig. S11). None of the patients showed an improvement in 
Patient Global Assessment (PaGA) ≥ 2 points, with a mean 
PaGa at baseline of 4.0 ± 0.7 to 4.0 ± 0.9 at week 12. Two 
patients had an improvement in DLQI ≥ 4 points, with a 
mean DLQI at baseline of 11.2 ± 6.8 to 8.8 ± 7.5 at week 
12. One patient had an improvement in PSQI ≥ 3 points, 
with a mean PSQI at baseline of 11.4 ± 4.9 to 12.0 ± 5.2 at 
week 12 (Fig. 1). None of the patients had an increase in 
BDI compared with baseline.
No severe adverse events were observed. For 5 patients 
an adverse event was registered, with diarrhoea, nausea, 
and abdominal pain being the most frequent. In one patient 
recurrent fever was registered.
Cytokines or chemokines were investigated in biopsies 
from the patients. In 2/6 and 1/6 biopsies from week 12 
data were missing for IL-31 and IL-22, respectively. None 
of the investigated cytokines or chemokines changed 
significantly during treatment with apremilast; however, 
a tendency to a decrease in concentrations at week 12 
compared with baseline was seen for IL-6, IL-10, IL-31, 
tumour necorsis factor (TNF)-α, INF-γ, CCL2, and CCL3. 
The Th17-derived cytokines, IL-17 and IL-22, were al-
most unchanged (Fig. S21). 
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Fig. 1. Change in visual analogue scale (VAS) – pruritus, Physician 
Global Assessment (PGA), Patient Global Assessment (PaGA), 
Dermatology Life Quality Index (DLQI), and Pittsburgh Sleep 
Quality Index (PSQI) over a period of 16 weeks of apremilast treatment 
in patients with prurigo nodularis (PN). End of treatment was at week 12. 
For data from 4 of the 10 patients the last observation was carried forward 
from week 4 due to drop-outs.
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DISCUSSION
This study found that 12 weeks of treatment with apremi-
last did not reduce pruritus in most patients (70%), thus 
no improvement was found in QoL or quality of sleep. 
Furthermore, apremilast was unable to clinically reduce the 
severity of PN. These results were supported by no signifi-
cant changes in concentrations of cytokine or chemokine. 
In a study by Samrao et al. (9), pruritus in patients with 
AD was significantly reduced within the first 2 weeks after 
initiation of apremilast. A rapid reduction in pruritus has 
also been observed in patients with psoriasis soon after 
initiation of apremilast (11). In the current study 3 of the 
10 patients experienced a reduction in pruritus ≥ 3 points, 
which was reported as early as 2 weeks after receiving 
apremilast; however, no clinical improvement or no sig-
nificant change in cytokines was seen in these patients. 
The pathogenesis of PN is poorly understood, and only 
a few molecular mediators of PN have been identified, it 
is possible that apremilast is unable to suppress the key 
molecules mediating PN. Apremilast is a PDE-4 inhibitor, 
which increases the intracellular level of cyclic adenosine 
monophosphate. The anti-pruritic effect of apremilast in 
AD and psoriasis may be explained by the modulation 
of a wide range of proinflammatory mediators, such as 
IL-22, IL-23, IL-31, IFN-γ, TNF-α and an upregulation 
of the anti-inflammatory mediator IL-10 (9, 11). In many 
pruritic skin diseases IL-31 is thought to induce pruritus, 
and it has also been found to be expressed in PN lesions 
(12, 13). A tendency was found towards a reduction in the 
concentration of IL-31; however, this was not significant. 
In agreement, IL-31 may not be as important in PN, as 
described earlier (5). This is supported by a recent trial 
by Zhong et al. (14), showing that IL-31 was expres-
sed significantly more in patients with PN who have a 
history of AD compared with patients with PN and no 
history of AD.
This study found that IL-10, an anti-inflammatory 
cytokine, was decreased, although this was not signifi-
cant. This is in line with a trial by Schafer et al. (15), in 
which patients with psoriatic arthritis were treated with 
apremilast and a decrease in IL-10 was observed during 
the initial 16 weeks of treatment despite amelioration of 
arthritis symptoms. 
The strengths of this study were: this is the first trial to 
evaluate the efficacy of apremilast in a group of patients 
with moderate to severe PN. The efficacy of apremilast 
was evaluated using both clinical parameters and by mea-
suring changes in expression of cytokines.
Study limitations include: this was a small study with 
only 10 patients, 3 of whom did not complete the trial. 
Furthermore, the study was designed as an unblinded 
proof-of-concept study with no placebo-controlled group.
In conclusion, this study found that 12 weeks of treat-
ment with apremilast did not reduce pruritus in a majority 
of patients with PN, with no improvement in QoL or sleep. 
Furthermore, the clinical severity of PN and expression of 
cytokines were unchanged with this treatment.
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